In-house activity detail

Details about the lobbying activity

To actively promote the value of the pharmaceutical industry for Yukon’s economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in the Yukon. As part of the initiatives, Organon Canada Inc. seeks to have its products listed on the Yukon Drug Formulary and enhance publicly funded women’s health initiatives/programs. Organon Canada also seeks to contribute to the Yukon’s economic prosperity by recommending policies that will attract increased investment. Activities could include providing recommendations on tax policies, research programs and policies, as well as policies and programs regarding innovation. Focus of lobbying efforts will be is on representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in the Yukon, including under Yukon Drug Formulary. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into any of the Yukon’s drug plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products. Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.